Monograph

N02CC05 - Almotriptan

Propably not porphyrinogenic

PNP

Rationale

Probably not affecting hepatic CYPs.

Therapeutic characteristics

Vascular 5HT-receptor agonist used in migraine.

Metabolism and pharmacokinetics

Eliminated by oxidative deamination via monamine oxidase. CYP 3A4 and2D6 are alo involved in its metabolism. In vitro studies show that almotriptan is not expected to affect the metabolism of CYP-metabolized drugs.

Personal communication

Badminton M (2006): Almotriptan has been used without any adverses effects in a 17 yr old female with VP (no previous attacks).

IPNet drug reports

One report of a possible beginning of an acute porphyric attack in a susceptible female with AIP, but the attack was poorly documented and several other factors could explain the symptoms. This report has therefore not been taken into account in the judgement of the porphyrinogenicity of almotriptan. Uneventful use reported in 1 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes N02C / N02CC or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Almogran · Almogran 12,5 mg, filmomhulde tablet · Almogran 12,5 mg, filmomhulde tabletten · Almotriptan · Almotriptan Eureco-Pharma 12,5 mg filmomhulde tabletten

Belgium